MSH2 and cancer: Furthermore, MSH6 and PMS2 mutations show reduced age-specific penetrance, resulting in higher average ages at onset of various cancers in MSH6 [52] and PMS2 [50, 53] carriers compared to MSH2 or MLH1 mutation carriers, although family- and/or mutation-specific variations exist.